Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H 2 receptor antagonist, a serotonin 5-HT 4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
1. A method of stimulating colonic motility and treating post-operative ileus of the colon in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of ipamorelin or a pharmaceutically acceptable salt, thereof, wherein said post-operative ileus is induced via opioid use.
2. The method of claim 1 wherein said post-operative ileus is induced via opioid use and gastrointestinal surgery.
3. The method of claim 1 comprising injection administration.
4. The method of claim 1 , wherein said treatment consists essentially of said administration.
5. The method of claim 1 comprising administration of from 0.01-2,600 mg of ipamorelin per day.
6. A method of simultaneously treating post-operative ileus of the colon and opioid-induced gastric stasis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of ipamorelin or a pharmaceutically acceptable salt, thereof.
7. The method of claim 6 comprising injection administration.
8. The method of claim 6 wherein said treatment consists essentially of said administration.
9. The method of claim 6 comprising administration of from 0.01-2,600 mg of ipamorelin per day.
10. The method of claim 6 wherein said patient is recovering from abdomen surgery.
11. A method of treating post-operative ileus in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of ipamorelin or a pharmaceutically acceptable salt thereof, wherein said post-operative ileus is induced via opioid use.
12. The method of claim 11 wherein said post-operative ileus is induced via opioid use and gastrointestinal surgery.
13. The method of claim 11 comprising injection administration.
14. The method of claim 11 wherein said treatment consists essentially of said administration.
15. The method of claim 11 comprising administration of from 0.01-2,600 mg of ipamorelin per day.
16. The method of claim 11 wherein said patient is recovering from abdomen surgery.